A detailed history of Nuveen Asset Management, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 335,314 shares of ARWR stock, worth $6.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
335,314
Previous 338,036 0.81%
Holding current value
$6.79 Million
Previous $8.79 Million 26.11%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.36 - $29.54 $52,697 - $80,407
-2,722 Reduced 0.81%
335,314 $6.49 Million
Q2 2024

Aug 09, 2024

BUY
$21.87 - $28.24 $218,765 - $282,484
10,003 Added 3.05%
338,036 $8.79 Million
Q1 2024

May 13, 2024

SELL
$27.21 - $39.48 $448,175 - $650,275
-16,471 Reduced 4.78%
328,033 $9.38 Million
Q4 2023

Feb 14, 2024

BUY
$21.2 - $31.03 $1.67 Million - $2.44 Million
78,558 Added 29.54%
344,504 $10.5 Million
Q3 2023

Nov 14, 2023

SELL
$26.2 - $36.08 $1.02 Million - $1.4 Million
-38,741 Reduced 12.72%
265,946 $7.15 Million
Q2 2023

Aug 14, 2023

BUY
$25.16 - $41.38 $690,918 - $1.14 Million
27,461 Added 9.91%
304,687 $10.9 Million
Q1 2023

May 15, 2023

SELL
$23.68 - $38.51 $2.7 Million - $4.39 Million
-114,101 Reduced 29.16%
277,226 $7.04 Million
Q4 2022

Feb 14, 2023

SELL
$28.0 - $40.56 $2.38 Million - $3.45 Million
-85,048 Reduced 17.85%
391,327 $15.9 Million
Q3 2022

Nov 14, 2022

SELL
$29.63 - $48.31 $6.63 Million - $10.8 Million
-223,901 Reduced 31.97%
476,375 $15.7 Million
Q2 2022

Aug 15, 2022

BUY
$27.79 - $50.61 $1.79 Million - $3.26 Million
64,342 Added 10.12%
700,276 $24.7 Million
Q1 2022

May 16, 2022

BUY
$39.62 - $69.97 $4.84 Million - $8.54 Million
122,084 Added 23.76%
635,934 $28.9 Million
Q4 2021

Feb 14, 2022

BUY
$58.09 - $82.51 $1.55 Million - $2.2 Million
26,687 Added 5.48%
513,850 $34.1 Million
Q3 2021

Nov 12, 2021

SELL
$58.38 - $84.96 $1.38 Million - $2.01 Million
-23,710 Reduced 4.64%
487,163 $30.4 Million
Q2 2021

Aug 16, 2021

SELL
$62.15 - $90.32 $1.2 Million - $1.74 Million
-19,285 Reduced 3.64%
510,873 $42.3 Million
Q1 2021

May 17, 2021

SELL
$61.35 - $90.47 $11.1 Million - $16.3 Million
-180,190 Reduced 25.37%
530,158 $35.2 Million
Q4 2020

May 17, 2021

BUY
$43.82 - $85.37 $22,348 - $43,538
510 Added 0.07%
710,348 $54.5 Million
Q4 2020

Feb 16, 2021

SELL
$43.82 - $85.37 $56,440 - $109,956
-1,288 Reduced 0.18%
709,838 $54.5 Million
Q3 2020

Nov 16, 2020

SELL
$33.21 - $51.27 $2.32 Million - $3.58 Million
-69,875 Reduced 8.95%
711,126 $30.6 Million
Q2 2020

Aug 14, 2020

BUY
$26.12 - $43.27 $2.5 Million - $4.14 Million
95,604 Added 13.95%
781,001 $33.7 Million
Q1 2020

May 14, 2020

BUY
$20.56 - $63.12 $6.45 Million - $19.8 Million
313,496 Added 84.3%
685,397 $19.7 Million
Q4 2019

Feb 14, 2020

SELL
$28.14 - $73.01 $622,484 - $1.62 Million
-22,121 Reduced 5.61%
371,901 $23.6 Million
Q3 2019

Nov 14, 2019

BUY
$26.26 - $34.86 $581,921 - $772,497
22,160 Added 5.96%
394,022 $11.1 Million
Q2 2019

Aug 15, 2019

BUY
$17.43 - $28.82 $6.48 Million - $10.7 Million
371,862 New
371,862 $9.85 Million

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.14B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.